pentapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-25. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
==== First-pass metabolism ==== During a typical drinking session, approximately 90% of the metabolism of ethanol occurs in the liver. Alcohol dehydrogenase and aldehyde dehydrogenase are present at their highest concentrations (in liver mitochondria). But these enzymes are widely expressed throughout the body, such as in the stomach and small intestine. Some alcohol undergoes a first pass of metabolism in these areas, before it ever enters the bloodstream.
In the above example, the combination of whole rice and canned chickpeas has no limiting amino acids. This means that consuming only rice and chickpeas, in these specific quantities of 306 g/day and 261 g/day respectively, for long periods of time, would easily combine to create complete protein, as it would not result in any of the essential amino acid deficiency. As the data of the example show, all essential amino acids are found in a specific plant. However, one or more of them may be limiting. For this reason, vegan and vegetarian diets need to be varied in terms of plants consumed.
Hyphenated techniques LC–MS (liquid chromatography–mass spectrometry) GC–MS (gas chromatography–mass spectrometry) LC–DAD (liquid chromatography–diode array detection) CE–MS (capillary electrophoresis–mass spectrometry) Chromatographic methods HPLC (high performance liquid chromatography) GC (gas chromatography) UPLC (ultra performance liquid chromatography) Supercritical fluid chromatography Electrophoresis Preparative native polyacrylamide gel electrophoresis Ligand binding assays Dual polarisation interferometry ELISA (Enzyme-linked immunosorbent assay) MIA (magnetic immunoassay) RIA (radioimmunoassay) Mass spectrometry Nuclear magnetic resonance The most frequently used techniques are: liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS) for 'small' molecules and enzyme-linked immunosorbent assay (ELISA) for macromolecules.
=== 2014: show-cause notices === After sixteen months of investigations, ASADA issued show cause notices to 34 players from Essendon's 2012 player list on 12 June 2014, alleging that they had been administered Thymosin beta-4, having determined that it had sufficient evidence that this was the type of thymosin used in the program. Unlike AOD-9604, it was certain that Thymosin beta-4 was considered banned during the program. ASADA did not allege that the players had used the substances intentionally; rather, the club had knowingly injected the players with the banned substance, and that the players were unaware that it was illegal. The players had ten days to respond, which would be followed by a tribunal hearing in which the burden of proof fell on ASADA to prove that the banned substance was administered to the players. Under the anti-doping codes, players found guilty would receive, as a starting point, a two-year suspension; however, if they were able to demonstrate they were unwittingly given a prohibited substance, they may have been eligible for a 50 per cent reduction. The names of the 34 players were initially suppressed under court order, and were formally released only after the eventual guilty verdict in January 2016. While this was progressing, Essendon performed well under Mark Thompson during the 2014 season, finishing seventh on the ladder and being eliminated in the first week of the finals. Thompson left the club altogether after the season.
malnutrition and vitamin deficiency immunodeficiency poor oral hygiene recent illness (especially acute necrotizing ulcerative gingivitis, measles, malaria, or kwashiorkor), social and environmental factors such as maternal malnutrition and closely spaced pregnancies that result in offspring with weakened immune systems In 2026 a newly discovered bacterium, Treponema A, was found in tissue samples from current sufferers of the disease as well as in historic samples. Further research is needed to establish if this could be a causative factor.
Sources: en.wikipedia.org
=== Design === Some teams are developing interoperable solutions, but this is not common. Governments express concerns over data sovereignty. WHO established a "working group focused on establishing standards for a common architecture for a digital smart vaccination certificate to support vaccine(s) against COVID-19 and other immunizations". The COVID-19 Credentials Initiative hosted by Linux Foundation Public Health (LFPH) is a global initiative working to develop and deploy privacy-preserving, tamper-evident and verifiable credential certification projects based on the open standard Verifiable Credentials (VCs).
==== Cross-linking ==== Corneal collagen cross-linking is a developing treatment that aims to strengthen the cornea, however, according to a 2015 Cochrane review, there is insufficient evidence to determine if it is useful in keratoconus. In 2016, however, the FDA approved cross-linking surgery as a treatment for keratoconus and recommended that a registry system should be set-up to evaluate the long-term treatment effect. The Save Sight Keratoconus Registry is an international database of keratoconus patients that is tracking outcomes of cross-linking in patients with keratoconus.
== Mechanism of action == Two main ideas about how it might work have been proposed over the years. The first idea, which has been proven wrong, is that insulin makes cells more permeable, so that the chemotherapy drugs are absorbed faster into cells. The other idea is that insulin might cause the cells to start dividing, which makes them more susceptible to destruction of many cytotoxic chemotherapy drugs.
== Function == The melanocortin system is one of the mammalian body's tools to regulate food intake in a push-pull fashion. The only neurons known to release melanocortins are located in the arcuate nucleus of the hypothalamus. However, melanocortins are also produced by keratinocytes in response to UV exposure. Accordingly, there is a subpopulation called POMC neurons and one called AgRP neurons. When POMC neurons release α-MSH, appetite is decreased. On the other hand, when AgRP neurons release AgRP, appetite is stimulated. Leptin, the energy surfeit hormone, and Ghrelin, the hunger hormone, are upstream regulators of the melanocortin system in the brain. These hormones also regulate the release of peptides other than the melanocortins. Disturbance of the leptin-melanocortin pathway can lead to early onset obesity as well as various metabolic disorders and suppressed immune function.
== See also == Air Bridge Denial Program – American program against drug trafficking Laconia incident – War crime during the naval battles of the Second World War Battle of the Bismarck Sea – 1943 Allied attack on a Japanese convoy Japanese transport ship Buyo Maru – Japanese transport and hellship during World War II Ecuadorian conflict (2024–present) – Ecuadorian conflict against criminal groups in which the United States recently bombed
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.